Last edition
News about "biotechnology company"
AtaiBeckley Completes Patient Dosing in Phase 2b Trial of VLS-01 for Treatment-Resistant Depression
AtaiBeckley has completed dosing the final patient in its Phase 2b Elumina trial evaluating VLS-01 for treatment-resistant depression. The company expects topline results in the fourth quarter of 2026 and plans to expand the therapy into major depressive disorder and generalized anxiety disorder, subject to positive clinical outcomes.
Biotechnology Company | 07/07/2026 | By News Bureau
Armata Pharmaceuticals Receives FDA Fast Track Designation for AP-SA02 Bacteriophage Therapy
The FDA has granted Fast Track designation to Armata’s AP-SA02 therapy for the adjunct treatment of complicated Staphylococcus aureus bacteremia caused by MSSA and MRSA infections.
Biotechnology Company | 07/05/2026 | By News Bureau | 112
Cbio A/S has received regulatory approval to begin a Phase I/IIa trial of novoleucel, a next-generation T-cell therapy, in patients with recurrent Cervical Cancer.
Biotechnology Company | 16/03/2026 | By News Bureau | 147
Immunic Secures European Patent for Vidofludimus Calcium, Strengthening Long-Term Market Exclusivity
Immunic receives European patent protection for Vidofludimus Calcium dosing regimens, reinforcing intellectual property coverage and potentially extending exclusivity for the multiple sclerosis therapy in Europe until 2043.
Biotechnology Company | 12/03/2026 | By News Bureau | 104
Antengene Licenses ATG-201 to UCB in Deal Worth Up to USD 1.1 Billion for Autoimmune Disease Therapy
Antengene grants UCB exclusive global rights to develop and commercialise ATG-201, a CD19/CD3 bispecific T-cell engager targeting autoimmune diseases, in a deal worth over USD 1.1 billion in milestones and royalties.
Biotechnology Company | 06/03/2026 | By News Bureau | 178
NOVOS Reports Positive Clinical Trial Results Showing Improvements in Vascular Aging Markers
A randomised clinical trial led by the University of Surrey found that NOVOS Core significantly improved endothelial function, arterial flexibility and systolic blood pressure in adults over 40 compared with placebo.
Biotechnology Company | 20/02/2026 | By News Bureau | 587
Sobi has acquired Arthrosi Therapeutics, adding phase III gout candidate pozdeutinurad (AR882) to its portfolio, with trial results expected in 2026.
Biotechnology Company | 11/02/2026 | By News Bureau | 182
FDA Approves Tenpoint Therapeutics' Yuvezzi, First Dual-Action Eye Drop for Presbyopia
The US FDA has approved Yuvezzi (carbachol and brimonidine tartrate), the first dual-agent eye drop for presbyopia, offering significant near-vision improvement with favourable tolerability.
Biotechnology Company | 31/01/2026 | By News Bureau | 368
QureBio Reports Promising Phase Ib/II Data for Q-1802 in Advanced Gastric and GEJ Cancer
ASCO 2026 data show strong response rates and manageable safety for the bispecific antibody Q-1802 plus XELOX, supporting progression to a Phase III trial.
Biotechnology Company | 29/01/2026 | By News Bureau | 349
Olatec Therapeutics presented MJFF-funded preclinical data showing its oral NLRP3 inhibitor dapansutrile delivered disease-modifying effects across two translational Parkinson’s disease mouse models.
Biotechnology Company | 21/01/2026 | By News Bureau | 262
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy